Low doses interferon-α in the treatment of high-risk cutaneous melanoma

Annals of Oncology

Volumn 11, Issue 4, 2000, Pages 487-490

  Ascierto, P A ^a   Palmieri, G ^b   Strazzullo, M ^a   Daponte, A ^a   Botti, G ^a   Satriano, S M R ^a   Motti, M L ^a   Mozzillo, N ^a   Castello, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Institute of Molecular Genetics   (Italy)

Author keywords

Cutaneous malignant melanoma; Immunotherapy; Interferon

Indexed keywords

ALPHA INTERFERON;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; LYMPHATIC METASTASIS; MALE; MELANOMA; RISK FACTORS; SKIN NEOPLASMS;

EID: 0034127375     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008375418507     Document Type: Article

References (26)

1. Levine N, Meyskens FL. Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. Lancet 1980; 2: 224-6.
2. Lejeune FJ, Libert A. Melanoma-associated antigens: Prospects for clinical use. Eur J Cancer Clin Oncol 1985; 21: 1433-8.
3. Wilson BS, Giacomini P, Imai K et al. Human melanoma-associated antigens identified with monoclonal antibodies. Ric Clin Lab 1982; 12: 517-38.
4. Parmiani G, Fossati G, Taramelli D et al. Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer Metast Rev 1985; 4: 7-26.
5. Robbins PF & Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996; 8: 628-36.
6. Chouaib S, Asselin-Paturel C, Mami-Chouaib F et al. The host-immune conflict: From immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-7.
7. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S. DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J Exp Med Mar 1979; 149: 658-68.
8. Horikoshi T, Fukuzawa K, Hanada N et al. In vitro comparative study of the antitumor effects of human interferon-α, -β and -γ on the growth and invasive potential of human melanoma cells. J Dermatol 1995; 22: 631-6.
9. Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993; 100: 239S-44S.
10. Cohen GL, Falkson CI. Current treatment options for malignant melanoma. Drugs 1998; 55: 791-9.
11. Caraceni A, Gangeri L, Martini C et al. Neurotoxicity of interferon-α in melanoma therapy: Results from a randomized controlled trial. Cancer 1998; 83: 482-9.
12. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon-α-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
13. Ascierto PA, Palmieri G, Parasole R et al. Three-year treatment with recombinant interferon-α as adjuvant therapy of cutaneous malignant melanoma. Int J Mol Med 1999; 3: 303-6.
14. Castello G, Ruocco V, Satriano RA, Zarrilli D. Role of interferons in the therapy of melanoma. Melanoma Res 1992; 1: 311-25.
15. Ruocco V, Satriano RA, Castello G. Malignant melanoma: Biotherapeutic strategies for management with interferons. Clin Dermatol 1991; 9: 505-10.
16. Castello G, Comella P, Manzo T et al. Immunological and clinical effects of intramuscular rIFNα-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res 1993; 3: 43-9.
17. Creagan ET, Dalton RJ, Ahmann DL et al. Randomized surgical adjuvant clinical trial of recombinant interferon-α-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13: 2776-83.
18. Cascinelli N. Evaluation of efficacy of adjuvant rIFNα-2a in melanoma patients with regional node metastasis. Proc Am Soc Clin Oncol 1995; 14: A129.
19. Lee N, Ferguson J, Murphy J et al. Phase II trial of low-dose adjuvant α-interferon for patients with stage II and III melanoma. Melanoma Res 1997; 7: 168 (Abstr).
20. Rusciani L, Petraglia S, Alotto M et al. Postsurgical adjuvant therapy for melanoma. Evaluation of a three-year randomized trial with recombinant interferon-α after three and five years of follow-up. Cancer 1997; 79: 2354-60.
21. Grob JJ, Dreno B, de la Salmonière P et al. Randomised trial of interferon-α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905-10.
22. Pehamberger H, Soyer P, Steiner A et al. Adjuvant interferon-α-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16: 1425-9.
23. Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343: 913-4.
24. Cascinelli N, Belli F. The WHO low-dose adjuvant interferon study: An update. Melanoma Res 1997; 7: 164 (Abstr).
25. Kirkwood JM, Ibrahim J, Sondak V et al. Role of high-dose IFN in high-risk melanoma: Preliminary results of the E1690/S9111/ C9190 US intergroup postoperative adjuvant trial of high- and low-dose IFNα2b (HDI and LDI) in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684 (Abstr). http://ecog.dfci.harvard.edu/ ~ecogdba/general/el690_abstract.html, 19/11/98.
26. Ascierto PA, Palmieri G. Adjuvant therapy of cutaneous melanoma. Lancet 1999; 353: 328 (Letter).